Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Merck
Johnson and Johnson
Harvard Business School
Express Scripts

Last Updated: April 1, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,439,899

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,439,899
Title:Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
Abstract: A pharmaceutical combination comprising a topoisomerase I inhibitor, and an Hsp90 inhibitor according to the following formulae (I) (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein. ##STR00001##
Inventor(s): Proia; David (Newton, MA)
Assignee: Synta Pharmaceuticals Corp. (Lexington, MA)
Application Number:14/355,684
Patent Claims:1. A pharmaceutical composition comprising a topoisomerase I inhibitor and an Hsp90 inhibitor wherein the topoisomerase I inhibitor is Irinotecan, topotecan, camptothecin, 9-aminocamptothecin, GG-211, DX-8951f and SN-38; and wherein the Hsp90 inhibitor is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1- ,2,4]triazole, 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-- 2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof.

2. The pharmaceutical composition of claim 1, wherein the Hsp90 inhibitor is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy- -[1,2,4]triazole or a tautomer or a pharmaceutically acceptable salt thereof.

3. The pharmaceutical composition of claim 1, wherein the Hsp90 inhibitor is 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-y- l)-2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof.

4. The pharmaceutical composition of claim 1, wherein the topoisomerase I inhibitor is irinotecan.

5. The pharmaceutical composition of claim 1, wherein the Hsp90 inhibitor is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy- -[1,2,4]triazole, or a tautomer or a pharmaceutically acceptable salt thereof, and the topoisomerase I inhibitor is irinotecan.

6. The pharmaceutical composition of claim 1, wherein the Hsp90 inhibitor is 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-y- l)-2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof, and the topoisomerase I inhibitor is irinotecan.

7. The pharmaceutical composition of claim 1, further comprising one or more additional therapeutic agents selected from the group consisting of vandetanib, trastuzumab, temodar, dexamethasone, cisplatin, epirubicin, ifosfamide, oxaliplatin, mitoxantrone, vorinostat, carboplatin, interferon alpha, rituxumab, prednisone, cyclophosphamide, bendamustine, adriamycin, valproate, celecoxib, thalidomide, nelarabine, methotrexate, filgrastim, gemtuzumab ozogamicin, testosterone, clofarabine, cytarabine, everolimus, busulfan, capecitabine, pegfilgrastim, mesna, amrubicin, obatoclax, gefitinib, cyclosporine, dasatinib, temozolomide, thiotepa, plerixafor, mitotane, vincristine, doxorubicin, cixutumumab, endostar, fenofibrate, melphalan, sunitinib, rubitecan, enoxaparin, isotretinoin, tariquidar, pomalidomide, sorafenib, altretamine, idarubicin, rapamycin, zevalin, pravastatin, carmustine, nelfinavir, streptozocin, tirapazamine, aprepitant, lenalidomide, G-CSF, procarbazine, alemtuzumab, amifostine, valspodar, lomustine, oblimersen, temsirolimus, vinblastine, figitumumab, belinostat, niacinamide, tipifarnib, estramustine, erlotinib, bevacizumab, paclitaxel, docetaxel, Abraxane.RTM., pemetrexed, bortezomib, cetuximab, gemcitabine, 5-fluorouracil, leucovorin and tetracycline.

8. The pharmaceutical composition of claim 7, wherein the one or more therapeutic agents is selected from the list consisting of carboplatin, cisplatin, erlotinib, bevacizumab, bortezomib, paclitaxel, doxorubicin, docetaxel, mitoxantrone, cytarabine, 5-fluorouracil, leucovorin and vincristine.

9. The pharmaceutical composition of claim 8, wherein the one or more additional agents are 5-fluorouracil and leucovorin.

10. A method of treating cancer in a subject, comprising administering to the subject an effective amount of an Hsp90 inhibitor and an effective amount of a topoisomerase I inhibitor, wherein the topoisomerase I inhibitor is Irinotecan, topotecan, camptothecin, 9-aminocamptothecin, GG-211, DX-8951f and SN-38; wherein the Hsp90 inhibitor is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1- ,2,4]triazole, 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-- 2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof; and wherein the cancer is colorectal cancer, ovarian cancer or non-small cell lung cancer.

11. The method of claim 10, wherein the cancer is colorectal cancer.

12. The method of claim 10, wherein irinotecan is administered at a dose of between about 100 mg/m.sup.2 to about 200 mg/m.sup.2; and the amount of the Hsp90 inhibitor is from about 2 mg/m.sup.2 to about 260 mg/m.sup.2.

13. The method of claim 12, wherein the amount of the Hsp90 inhibitor is about 75 mg/m.sup.2, about 85 mg/m.sup.2, about 100 mg/m.sup.2, about 110 mg/m.sup.2, about 115 mg/m.sup.2, about 120 mg/m.sup.2, about 145 mg/m.sup.2, about 150 mg/m.sup.2, about 175 mg/m.sup.2, about 180 mg/m.sup.2, about 200 mg/m.sup.2, about 215 mg/m.sup.2 or about 260 mg/m.sup.2.

14. The method of claim 10, wherein the Hsp90 inhibitor is administered IV once weekly or twice weekly.

15. A method of inhibiting the growth of a cancer or tumor cell in a subject, comprising the steps of: (a) contacting the cell with an effective amount of an Hsp90 inhibitor, wherein the Hsp90 inhibitor is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1- ,2,4]triazole, 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-- 2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof, and (b) exposing the cell to an effective amount of a topoisomerase I inhibitor, wherein the topoisomerase I inhibitor is selected from the group consisting of irinotecan, topotecan, camptothecin, 9-aminocamptothecin, GG-211, DX-8951f, and SN-38; and wherein the cancer is colorectal cancer, ovarian cancer or non-small cell lung cancer.

16. The method of claim 15, wherein the compound is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1- ,2,4]triazole, or a tautomer or a pharmaceutically acceptable salt thereof and the topoisomerase I inhibitor is irinotecan.

17. The method of claim 15, wherein the compound is 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-- 2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof, and the topoisomerase I inhibitor is irinotecan.

Summary for Patent:   Start Trial

PCT Information
PCT FiledNovember 01, 2012PCT Application Number:PCT/US2012/063035
PCT Publication Date:May 10, 2013PCT Publication Number:WO2013/067162

Details for Patent 9,439,899

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial Synta Pharmaceuticals Corp. (Lexington, MA) 2031-11-02 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 002 1991-02-20   Start Trial Synta Pharmaceuticals Corp. (Lexington, MA) 2031-11-02 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 003 1991-02-20   Start Trial Synta Pharmaceuticals Corp. (Lexington, MA) 2031-11-02 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 004 1991-02-20   Start Trial Synta Pharmaceuticals Corp. (Lexington, MA) 2031-11-02 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Synta Pharmaceuticals Corp. (Lexington, MA) 2031-11-02 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Synta Pharmaceuticals Corp. (Lexington, MA) 2031-11-02 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Start Trial Synta Pharmaceuticals Corp. (Lexington, MA) 2031-11-02 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Colorcon
McKinsey
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.